B型肝炎帶原多年，57歲的李先生平時卻沒有定期追蹤檢查，一次健康檢查赫然發現肝臟中央冒出11公分大肝癌，且已轉移到肝臟左葉，確診為肝癌中期，被宣告時間不多了，但在醫師評估建議下最後接受經肝動脈化學栓塞術，成功縮小腫瘤，拚到可進行肝臟移植的門檻。
根據國內臨床統計顯示，肝癌中期的平均存活期為10多個月，5年存活率僅約2成，要拚一線生機，難度不小。
成大醫院移植外科主任林毅志表示，考量男子腫瘤分布與肝功能情形，已經無法手術切除，所幸，經肝動脈化學栓塞術見效，成功縮小腫瘤，達到可進行肝臟移植的標準，而即將步入婚姻的兒子也願意捐贈肝臟，肝臟移植手術十分成功，男子因此能續享天倫之樂。
肝癌長期占據國人主要死因之一，醫師提醒，其中慢性肝炎及肝硬化病患者是發生肝癌的高危險族群。
林毅志直言，肝臟已有病理變化的病人，必須同時考量腫瘤、肝機能及整體健康狀態，能接受積極手術切除的並不多，再加上病人接受治療後，已有慢性肝炎或肝硬化的剩餘肝臟，仍是發生肝癌的危險環境，復發機率很高，手術切除後的病人5年復發率高達5至7成，其他治療成效較差的病患則更高。
舉該名男子為例，林毅志強調，雖然剛診斷時的期別已超出移植標準，但經過栓塞等降階治療就可以達標，接受肝臟移植的存活率與原來就符合換肝標準不必降階治療的病人相當，5年復發率可以降到約1成。
林毅志說，積極治療是保命的重要關鍵，雖然每位病人病況不同，並非治療後都能成功降期，但及早發現即時治療，就有望延長生命。
Laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standa.rds
Hepatitis B has been used for many years. Mr. Li, 57, did not regularly follow up the examination. A health check revealed a large liver cancer of 11 cm in the center of the liver, and he had metastasized to the left lobe of the liver. He was diagnosed as having a mid-stage liver cancer. More, but after receiving the evaluation of the physician's assessment, he was finally subjected to transcatheter arterial chemoembolization, which successfully reduced the tumor and reached the threshold for liver transplantation.
According to domestic clinical statistics, the average survival time of liver cancer in the middle of the period is more than 10 months, and the 5-year survival rate is only about 20%. It is not difficult to fight a lifeline.
Lin Yizhi, director of the Department of Transplantation Surgery at Chengda Hospital, said that considering the distribution of men's tumors and liver function, it has been unable to be surgically removed. Fortunately, hepatic arterial chemoembolization has been effective, and the tumor has been successfully reduced to meet the criteria for liver transplantation. The son of the marriage is also willing to donate the liver. The liver transplant operation is very successful, so the man can enjoy the family fun.
Liver cancer has long occupied one of the main causes of death in Chinese people. Doctors reminded that patients with chronic hepatitis and cirrhosis are high-risk groups of liver cancer.
Lin Yizhi bluntly said that patients with pathological changes in the liver must consider the tumor, liver function and overall health status at the same time. There are not many active surgical resections. In addition, patients with chronic hepatitis or cirrhosis after treatment. The remaining liver is still a dangerous environment for liver cancer, and the chance of recurrence is high. The recurrence rate of patients after surgical resection is as high as 5 to 70%, and other patients with poor treatment results are higher.
Taking this man as an example, Lin Yizhi emphasized that although the period of diagnosis has exceeded the transplant standard, it can be achieved after embolization and other reduced-grade treatments. The survival rate of liver transplantation is not consistent with the standard of liver replacement. The treated patients are equivalent, and the 5-year recurrence rate can be reduced to about 10%.
Lin Yizhi said that active treatment is an important key to life-saving. Although each patient's condition is different, it is not a successful downgrade after treatment. However, early detection of immediate treatment is expected to prolong life.
根據國內臨床統計顯示，肝癌中期的平均存活期為10多個月，5年存活率僅約2成，要拚一線生機，難度不小。
成大醫院移植外科主任林毅志表示，考量男子腫瘤分布與肝功能情形，已經無法手術切除，所幸，經肝動脈化學栓塞術見效，成功縮小腫瘤，達到可進行肝臟移植的標準，而即將步入婚姻的兒子也願意捐贈肝臟，肝臟移植手術十分成功，男子因此能續享天倫之樂。
肝癌長期占據國人主要死因之一，醫師提醒，其中慢性肝炎及肝硬化病患者是發生肝癌的高危險族群。
林毅志直言，肝臟已有病理變化的病人，必須同時考量腫瘤、肝機能及整體健康狀態，能接受積極手術切除的並不多，再加上病人接受治療後，已有慢性肝炎或肝硬化的剩餘肝臟，仍是發生肝癌的危險環境，復發機率很高，手術切除後的病人5年復發率高達5至7成，其他治療成效較差的病患則更高。
舉該名男子為例，林毅志強調，雖然剛診斷時的期別已超出移植標準，但經過栓塞等降階治療就可以達標，接受肝臟移植的存活率與原來就符合換肝標準不必降階治療的病人相當，5年復發率可以降到約1成。
林毅志說，積極治療是保命的重要關鍵，雖然每位病人病況不同，並非治療後都能成功降期，但及早發現即時治療，就有望延長生命。
Laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standa.rds
Hepatitis B has been used for many years. Mr. Li, 57, did not regularly follow up the examination. A health check revealed a large liver cancer of 11 cm in the center of the liver, and he had metastasized to the left lobe of the liver. He was diagnosed as having a mid-stage liver cancer. More, but after receiving the evaluation of the physician's assessment, he was finally subjected to transcatheter arterial chemoembolization, which successfully reduced the tumor and reached the threshold for liver transplantation.
According to domestic clinical statistics, the average survival time of liver cancer in the middle of the period is more than 10 months, and the 5-year survival rate is only about 20%. It is not difficult to fight a lifeline.
Lin Yizhi, director of the Department of Transplantation Surgery at Chengda Hospital, said that considering the distribution of men's tumors and liver function, it has been unable to be surgically removed. Fortunately, hepatic arterial chemoembolization has been effective, and the tumor has been successfully reduced to meet the criteria for liver transplantation. The son of the marriage is also willing to donate the liver. The liver transplant operation is very successful, so the man can enjoy the family fun.
Liver cancer has long occupied one of the main causes of death in Chinese people. Doctors reminded that patients with chronic hepatitis and cirrhosis are high-risk groups of liver cancer.
Lin Yizhi bluntly said that patients with pathological changes in the liver must consider the tumor, liver function and overall health status at the same time. There are not many active surgical resections. In addition, patients with chronic hepatitis or cirrhosis after treatment. The remaining liver is still a dangerous environment for liver cancer, and the chance of recurrence is high. The recurrence rate of patients after surgical resection is as high as 5 to 70%, and other patients with poor treatment results are higher.
Taking this man as an example, Lin Yizhi emphasized that although the period of diagnosis has exceeded the transplant standard, it can be achieved after embolization and other reduced-grade treatments. The survival rate of liver transplantation is not consistent with the standard of liver replacement. The treated patients are equivalent, and the 5-year recurrence rate can be reduced to about 10%.
Lin Yizhi said that active treatment is an important key to life-saving. Although each patient's condition is different, it is not a successful downgrade after treatment. However, early detection of immediate treatment is expected to prolong life.
全站熱搜
留言列表
